
ALLO Stock Forecast & Price Target
ALLO Analyst Ratings
Bulls say
Allogene Therapeutics Inc's innovative approach to allogeneic T-cell therapy is underscored by promising clinical results, notably the impressive complete response (CR) rates of 100% and 82% in distinct patient categories, positioning the firm's cema-cel product competitively against approved autologous CAR-T therapies. The company's focus on logistically feasible and cost-effective cell therapies, combined with the potential for re-treatment and application in earlier treatment lines, suggests a robust pathway for accelerating patient uptake and meeting critical oncology needs. Furthermore, the anticipated review by the Data Safety Monitoring Board (DSMB) regarding event-free survival (EFS) analysis in early 2026 may yield insights that facilitate expedited development timelines, reinforcing the positive momentum in Allogene's clinical pipeline.
Bears say
Allogene Therapeutics Inc reported a net loss of $60 million, translating to an earnings per share (EPS) of ($0.28), indicating ongoing financial challenges exacerbated by the speculative nature of its clinical trials. The company's research and development expenses amounted to $44.9 million, which was lower than estimates, yet ongoing negative data from trials like UCART19 poses significant risks that could undermine investor confidence and delay potential approvals. Additionally, competition within the immuno-oncology sector could further diminish market share, heightening uncertainties around future revenue and elevating volatility in the company's stock price.
This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ALLO Analyst Forecast & Price Prediction
Start investing in ALLO
Order type
Buy in
Order amount
Est. shares
0 shares